ART Announces Receipt of Letter of Intent From CRO BioLaurus to Purchase Optix MX2 System
15 April 2008 - 2:10AM
Marketwired
MONTREAL, CANADA (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, is pleased to announce
that it has received a Letter of Intent (LOI) to purchase its
Optix� MX2 preclinical optical molecular imaging system, from the
Southern California-based CRO firm BioLaurus, Inc. The announcement
was made at the annual AACR meeting in San Diego, which ART is
attending as an exhibitor.
Dr. Mario Bourdon, President of BioLaurus, stated, "BioLaurus
has developed a platform for longitudinal preclinical trials in
response to the objectives of the FDA's "Critical Path Initiative",
aimed at accelerating drug development. BioLaurus will provide the
ART Optix MX2 system to its pharmaceutical and biotechnology
clients, as part of its multi-modality quantitative molecular
imaging capabilities."
"We are proud to partner with BioLaurus, a state-of-the-art CRO
that has developed a tremendously valuable and cutting-edge service
offering - ensuring their long term success - and we are honoured
to be a part of that," said Sebastien Gignac, ART's President and
CEO. "The Optix imaging system provides the most comprehensive
molecular imaging data set on the market today and BioLaurus'
decision to offer Optix to their rapidly expanding client base is
further validation that Optix should be used when molecular
information is critically important," concluded Mr. Gignac.
BioLaurus is a San Diego-based company focusing on the
preclinical segment of the rapidly growing CRO industry. BioLaurus
provides research services in drug discovery and IND enabling drug
development for pharmaceutical and biotechnology companies. These
services comprise in vitro and in vivo efficacy, PK/ADME, safety,
and toxicology services, with both conventional and new
leading-edge technologies such as in vitro HCA/HCS and in vivo
quantitative molecular imaging and microdialysis/LC/MS.
About the Optix� system
Based on time-domain technology, which allows measurement of the
light's time of arrival, the Optix� in vivo optical molecular
imaging device is the most sensitive optical imager commercially
available on the preclinical market, allowing for detection of
lower concentrations of signals deeper inside the body. Unique to
the Optix system is the ability to recover fluorescence lifetime,
which can be used to separate and quantify probe distributions
depending on their respective biochemical environment. Also part of
the Optix product offering is a new CT fusion software package
allowing researchers to export the scan obtained using Optix in
DICOM format, and fuse it with microCT for a full 3D anatomical
reference.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan� optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. ART is commercializing
these products in a global strategic alliance with GE Healthcare, a
world leader in mammography and imaging. Finally, the Fenestra�
line of molecular imaging contrast products provide image
enhancement for a wide range of preclinical Micro CT applications
allowing scientists to see greater detail in their imaging studies,
with potential extension into other major imaging modalities. ART's
shares are listed on the TSX under the ticker symbol ARA. For more
information on ART, visit our website at www.art.ca .
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2007, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer 514-832-0777 jbedard@art.ca ART Advanced
Research Technologies Inc. Dino DiCamillo, Vice President, Global
Sales and Marketing, Preclinical Imaging 514-832-0777
ddicamil@art.ca www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024